Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia
Part of paid clinical trials in Albuquerque, New Mexico.
- Sponsor
- University of New Mexico
- Study ID
- NCT01169909
- Phase
- PHASE1
- Status
- Completed
Conditions
- Pterygium
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Ranibizumab — DRUGSubtenon injections of Ranibizumab 0.5mg will be given, and repeated twice with 30 day intervals between each dose. Note, after an amendment in February 2011, this dose was increased to 2mg with the same schedule.
Study Details
Ranibizumab, an effective antineovascular drug, will be studied for safety and efficacy in pterygium, a neovascular disorder of the ocular surface.
Key Dates
- First listed
- Jul 26, 2010
- Start date
- Aug 31, 2010
- Status verified
- May 2016
- Primary completion
- Jul 31, 2014
- Completion
- Jul 31, 2014
Study Design
- Enrollment
- 10 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Ranibizumab treatmentPatients will receive a sub-tenons injection of Ranibizumab 0.5mg, to be repeated twice with 30 day intervals between each dose.
Primary Outcome Measure
Safety [ Time Frame: Within the first 30 days after injection ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of New Mexico Health Science Center | Albuquerque | New Mexico | 87106 | - |
Find similar trials in Albuquerque, NM
By research site